Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13820380 | 0.82 | CRBN (0.38) | TP53NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL11420601 | 0.75 | MAPT (0.61) | TP53NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL25680277 | 0.74 | HPGD (0.47) | TP53NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL25680280 | 0.74 | TP53 (0.46) | TP53NAMPTMAPTALDH1A1LMNA | |
| SCHEMBL26445737 | 0.70 | MAPT (0.47) | TP53RAB9ASMN1; SMN2NAMPTMAPT | |
| SCHEMBL5134832 | 0.70 | TP53 (0.60) | TP53NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17874890 | 0.68 | HPGD (0.47) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11315413 | 0.68 | L3MBTL1 (0.52) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13892196 | 0.68 | POLB (0.49) | TP53NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL13880993 | 0.68 | HDAC1 (0.51) | NAMPTMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765920-B2 | Tyrosine bioconjugation through aqueous Ene-like reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | THE SCRIPPS RESEARCH INSTITUTE | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | TP53 1507/4885NPC1 4884/4885RAB9A 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.